Barrett's esophagus and Barrett's carcinoma

Current Oncology Reports

Volumn 5, Issue 3, 2003, Pages 203-209

  von Rahden, Burkhard H A ^b   Stein, Hubert J ^a   Siewert, Jörg R ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; CYCLIN D1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLUTATHIONE TRANSFERASE; MYC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; ROFECOXIB; STOMACH SECRETION INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN;

ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ENDOSCOPIC SURGERY; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HUMAN; INTESTINE EPITHELIUM; JEJUNUM INTERPOSITION; LYMPHADENECTOMY; MALIGNANT TRANSFORMATION; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PREOPERATIVE RADIOTHERAPY; QUALITY OF LIFE; REVIEW; SQUAMOUS EPITHELIUM; SURGICAL TECHNIQUE; ADENOCARCINOMA; ESOPHAGUS TUMOR; INCIDENCE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE;

EID: 0043237711     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0111-x     Document Type: Review

References (66)

1. Shaheen N, Ransohoff DF: Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002, 287:1972-1981.
2. Spechler SJ: Clinical practice: Barrett's esophagus. N Engl J Med 2002, 346:836-842.
3. Wijnhoven BP, Louwman MW, Tilanus HW, Coebergh JW: Increased incidence of adenocarcinomas at the gastro-oesophageal junction in Dutch males since the 1990s. Eur J Gastroenterol Hepatol 2002, 14:115-122.
4. Bareiss D, Stabenow R, Muller R, et al.: Current epidemiology of carcinoma of the esophagus and cardia in Germany [in German]. Dtsch Med Wochenschr 2002, 127:1367-1374.
5. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002, 95:2096-2102.
6. Vaughan TL, Kristal AR, Blount PL, et al.: Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002, 11:745-752.
7. Cameron AJ: Epidemiology of Barrett's esophagus and adenocarcinoma. Dis Esophagus 2002, 15:106-108.
8. Gerson LB, Shetler K, Triadafilopoulos G: Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002, 123:461-467.
9. Avidan B, Sonnenberg A, Schnell TG, et al.: Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002, 97:1930-1936.
10. Romero Y, Cameron AJ, Schaid DJ, et al.: Barrett's esophagus: prevalence in symptomatic relatives. Am J Gastroenterol 2002, 97:1127-1132.
11. Chak A, Lee T, Kinnard MF, et al.: Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002, 51:323-328.
12. Falk GW: Barrett's esophagus. Gastroenterology 2002, 122:1569-1591.
13. van Sandick JW, van Lanschot JB, van Felius L, et al.: Intestinal metaplasia of the esophagus or esophagogastric junction: evidence of distinct clinical, pathologic, and histochemical staining features. Am J Clin Pathol 2002, 117:117-125.
14. Cameron AJ, Souto EO, Smyrk TC: Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am J Gastroenterol 2002, 97:1375-1380.
15. Goldblum JR: The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol 2002, 6:67-73.
16. Odze R. Cytokeratin 7/20 immunostaining: Barrett's oesophagus or gastric intestinal metaplasia? Lancet 2002, 359:1711-1713.
17. Shen B, Ormsby AH, Shen C, et al.: Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction. Cancer 2002, 94:820-831.
18. Taniere P, Borghi-Scoazec G, Saurin JC, et al.: Cytokeratin expression in adenocarcinomas of the esophagogastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach. Am J Surg Pathol 2002, 26:1213-1221.
19. Siewert JR, Stein HJ: Classification of carcinoma of the oesophagogastric junction. Br J Surg 1998, 85:1457-1459.
20. Siewert JR, Feith M, Werner M, Stein HJ: Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000, 232:353-361.
21. Theisen J, Stein HJ, Dittler HJ, et al.: Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc 2002, 16:671-673.
22. Kauer WK, Stein HJ: Role of acid and bile in the genesis of Barrett's esophagus. Chest Surg Clin N Am 2002, 12:39-45.
23. Souza RF, Shewmake K, Terada LS, Spechler SJ: Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002, 122:299-307.
24. Kaur BS, Triadafilopoulos G: Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002, 283:G327-G334.
25. Krishnan K, Brenner DE: Prostaglandin inhibitors and the chemoprevention of noncolonic malignancy. Gastroenterol Clin North Am 2001, 30:981-1000.
26. Zhang F, Altorki NK, Wu YC, et al.: Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 2001 121:1391-1399.
27. Buskens CJ, Van Rees BP, Sivula A, et al.: Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002, 122:1800-1807.
28. Jenkins GJ, Doak SH, Parry JM, et al.: Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 2002, 89:824-837.
29. Bian YS, Osterheld MC, Fontolliet C, et al.: p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002, 122:1113-1121.
30. Geddert H, Heep HJ, Gabbert HE, Sarbia M: Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus. Cancer 2002, 94:212-218.
31. Geddert H, Zeriouh M, Wolter M, et al.: Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol 2002, 118:60-66.
32. Brabender J, Lord RV, Wickramasinghe K, et al.: Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastrointest Surg 2002, 6:359-367.
33. van der Woude CJ, Jansen PL, Tiebosch AT, et al.: Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Hum Pathol 2002, 33:686-692.
34. Tselepis C, Perry I, Dawson C, et al.: Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002, 21:6071-6081.
35. Sampliner RE: The Practice Parameters Committee of the American College of Gastroenterology: updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002, 97:1888-1895.
36. Spechler SJ: Screening and surveillance for complications related to gastroesophageal reflux disease. Am J Med 2001, 111(Suppl 8A):130S-136S.
37. van Blankenstein M: Barrett's esophagus: so what! Dis Esoph 2002, 15:1-4.
38. Gerson LB, Triadafilopoulos G: Screening for esophageal adenocarcinoma: an evidence-based approach. Am J Med 2002, 113:499-505.
39. Cooper GS, Yuan Z, Chak A, Rimm AA: Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer 2002, 95:32-38.
40. Incarbone R, Bonavina L, Saino G, et al.: Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002, 16:263-266.
41. Kaur BS, Khamnehei N, Iravani M, et al.: Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002, 123:60-67.
42. Buttar NS, Wang KK, Leontovich O, et al.: Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122:1101-1112.
43. Schlemper RJ, Riddell RH, Kato Y, et al.: The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000, 47, 251-255.
44. Werner, M, Flejou, J F, Hainaut, P, et al.: Adenocarcinoma of the oesophagus. In World Health Organization Classification of Tumours: Patholgy and Genetics - Tumours of the Digestive System. Edited by Hamilton SR, Aaltonen, L. Lyon, France: IARC Press; 2000:20-25.
45. Ormsby AH, Petras RE, Henricks WH, et al.: Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002, 51:671-676.
46. Walker SJ, Selvasekar CR, Birbeck N: Mucosal ablation in Barrett's esophagus. Dis Esophagus 2002, 15:22-29.
47. Ortner MA, Zumbusch K, Liebetruth J, et al.: Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study. Endoscopy 2002, 34:611-616.
48. Ahmad NA, Kochman ML, Long WB, et al.: Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: a study of 101 cases. Gastrointest Endosc 2002, 55:390-396.
49. Schnell, TG, Sontag, SJ, Chejfec, G, et al.: Long-term nonsurgical management of Barrett's esophagus with high grade dysplasia. Gastroenterology 2001, 120:1607-1619.
50. Pacifico RJ, Wang KK: Nonsurgical management of Barrett's esophagus with high-grade dysplasia. Surg Oncol Clin N Am 2002, 11:321-336.
51. DeMeester TR. Surgical therapy for Barrett's epophagus: prevention, protection and excision. Dis Esophagus 2002, 15:109-116.
52. Headrick JR, Nichols FC, Miller DL, et al.: High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thor Surg 2002, 73:1697-1703.
53. Reid BJ, Levine DS, Longton G, et al.: Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000, 95:1669-1676.
54. Stein HJ, Feith M, Müller J, et al.: Limited resection for early Barrett's cancer. Ann Surg 2000, 232:733-742.
55. Banki F, Mason RJ, DeMeester SR, et al.: Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg 2002, 236:324-335.
56. Buttar NS, Wang KK, Lutzke LS, et al.: Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 2001, 54:682-688
57. May A, Gossner L, Pech O, et al.: Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy 2002, 34:604-610.
58. Siewert JR, Stein HJ, Sendler A, et al.: Esophageal cancer: clinical management. In Gastrointestinal Oncology: Principles and Practice. Edited by Kelsen DA, et al. Philadelphia: Lippincott Williams & Wilkins; 2002:261-288.
59. Birkmeyer JD, Siewers AE, Finlayson EV, et al.: Hospital volume and surgical mortality in the United States. N Engl J Med 2002, 346:1128-1137.
60. Stein HJ, Brücher BLDM, Sendler A, Siewert JR: Esophageal cancer: patient evaluation and pretreatment staging. Surg Oncol 2001, 10:103-111.
61. Altorki N, Kent M, Ferrara C, Port J: Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002, 236:177-183.
62. Hulscher JB, van Sandick JW, de Boer AG, et al.: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347:1662-1669.
63. Stein, HJ, Sendler A, Fink U, Siewert JR: Multidisciplinary approach to esophageal and gastric cancer. Surg Clin N Am 2000, 80:659-682.
64. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727-1733.
65. Weber WA, Ott K, Becker K, et al.: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001, 19:3058-3065.
66. Flamen P, Van Cutsem E, Lerut A, et al.: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002, 13:361-368.